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Metastasis is the leading cause of cancer death. A tumor-supportive microenviron-
ment, or premetastatic niche, at potential secondary tumor sites plays an important
role in metastasis, especially in tumor cell colonization. Although a fibrotic milieu is
known to promote tumorigenesis and metastasis, the underlying molecular contribu-
tors to this effect have remained unclear. Here we show that periostin, a compo-
nent of the extracellular matrix that functions in tissue remodeling, has a key role in
formation of a fibrotic environment that promotes tumor metastatic colonization.
We found that periostin was widely expressed in fibrotic lesions of mice with bleo-
mycin-induced lung fibrosis, and that up-regulation of periostin expression coincided
with activation of myofibroblasts positive for a-smooth muscle actin. We estab-
lished a lung metastasis model for B16 murine melanoma cells and showed that
metastatic colonization of the lung by these cells was markedly promoted by bleo-
mycin-induced lung fibrosis. Inhibition of periostin expression by giving an intratra-
cheal antisense oligonucleotide targeting periostin mRNA was found to suppress
bleomycin-induced lung fibrosis and thereby to attenuate metastatic colonization of
the lung by melanoma cells. Our results indicate that periostin is a key player in the
development of bleomycin-induced fibrosis and consequent enhancement of tumor
cell colonization in the lung. Our results therefore implicate periostin as a potential
target for prevention or treatment of lung metastasis.
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1 | INTRODUCTION
Lung metastasis is a major contributor to poor prognosis in many
types of cancer, but the mechanisms of such metastasis remain
largely unclear.1,2 The formation of a tumor-supportive
microenvironment, or premetastatic niche, by stromal components
and immune cells is required for the colonization and propagation of
circulating tumor cells at secondary or distant organs.3 Remodeling
of the extracellular matrix (ECM) is key to premetastatic niche for-
mation and is induced by various events such as inflammation and
tissue injury.4 Fibrosis is a result of ECM remodeling. Preclinical data
suggest that a fibrotic milieu promotes tumor cell colonization,5,6
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and smoking, one of the risk factors for pulmonary fibrosis, has been
indicated to have an association with lung metastasis in breast can-
cer patients,7 although the underlying molecular mechanism of this
effect is unknown.
Periostin is a secreted ECM protein that plays various roles in
tissue development and regeneration as well as contributing to con-
ditions and diseases such as inflammation, allergy, fibrosis, and can-
cer.8 A high level of periostin expression is associated with various
types of cancer, including lung, breast, colorectal, and pancreatic
cancer as well as melanoma.9 Periostin is also implicated in lung
metastasis of breast cancer as an important component of a cancer
stem cell-supportive niche,10 and it activates a-smooth muscle actin
(a-SMA)-positive myofibroblasts and thereby promotes formation of
a fibrotic microenvironment to sustain the metastatic growth of pan-
creatic cancer.6 We previously reported that high mRNA expression
of POSTN, FN1, and COL1A1 was detected in the metastatic region
of a melanoma patient by gene expression analysis, and that perios-
tin was highly expressed during the wound-healing process.11 Perios-
tin was considered to be the most feasible therapeutic target among
these ECM proteins because mice deficient in Fn1 or Col1a1 are
embryonic lethal12,13 whereas mice deficient in Postn develop nor-
mally. Thus, we showed that inhibition of periostin significantly
reduced the incidence of melanoma metastasis to wound sites.11
Although periostin is known to be an essential factor for fibrotic
responses in idiopathic interstitial pneumonia in both mice and
humans,14,15 the relation between its role in lung fibrosis and lung
metastasis of tumor cells is not well defined.
We have now established mice with pulmonary fibrosis
induced by bleomycin as a lung metastasis model for melanoma.
We found that fibrosis enhanced metastatic colonization of the
lung of these animals by B16 murine melanoma cells, and that
periostin contributed to formation of this premetastatic niche
through activation of a-SMA+ myofibroblasts. Furthermore, giving
an intratracheal antisense oligonucleotide that targets periostin
mRNA attenuated periostin expression as well as suppressed bleo-
mycin-induced lung fibrosis and metastatic colonization of the lung
by melanoma cells.
2 | MATERIALS AND METHODS
2.1 | Mice
Female C57BL/6J mice aged 6-10 weeks (Sankyo Labo Service Cor-
poration, Tokyo, Japan) were studied. All animal experiments were
carried out in accordance with protocols approved by the Ethics
Committee of Keio University.
2.2 | Cell lines
Murine melanoma cell lines B16 and B16-BL6 were obtained from
RIKEN Cell Bank (Tsukuba, Japan). Cells were cultured in DMEM
supplemented with 10% FBS and penicillin-streptomycin (Nacalai
Tesque, Kyoto, Japan).
2.3 | Antisense oligonucleotides
Antisense oligonucleotides (ASO) were prepared by Axolabs (Kulm-
bach, Germany). The nucleotide sequence of an ASO targeting
mouse periostin mRNA is 50-mC*A*mC*mC*A*mc*t*g*t*t*
mc*g*t*a*a*U*U*U*G*G-30 and that of a control oligonucleotide is
50-mC*G*A*mC*A*t* mc*g*t*g*mc*g*t* mc*g*U*A*U*A*U-30, with
lowercase letters indicating deoxyribonucleotides and underlined
uppercase letters denoting 20-O-methyl-ribonucleotides. The nucle-
obases indicated as mC and mc are 5-methylcytosine. Asterisks indi-
cate that internucleotide linkages are phosphorothioate.
2.4 | In vivo studies
For establishment of a lung metastasis model, 50 lL (0.025 U) bleo-
mycin (Cayman Chemical, Ann Arbor, MI, USA) or 50 lL saline were
given to mice intratracheally. After 10 days, B16 cells (1 9 105)
were injected into the tail vein, and the mice were killed 11 days
later. For evaluation of the time course of lung fibrosis induced by
bleomycin, mice were killed 4, 8, 12, and 16 days after receiving
bleomycin. Non-treated mice were examined as the time 0 control.
For analysis of the effect of giving ASO on fibrosis, mice were trea-
ted intratracheally with control or 100 lg periostin ASO 2 and
7 days after receiving bleomycin and were killed 8 days after receiv-
ing bleomycin. For analysis of the effect of ASO dosage on metasta-
sis, mice were treated intratracheally with control or periostin ASO
at 2 and 7 days, injected into the tail vein with B16 cells at 10 days,
and killed at 21 days after receiving bleomycin.
2.5 | Tissue histology
Mice were killed by ip injection of pentobarbital (Kyoritsu Seiyaku,
Tokyo, Japan), and perfused through the right cardiac ventricle with
PBS. The lungs were inflated with 4% paraformaldehyde, dissected,
incubated in 4% paraformaldehyde overnight, and embedded in
paraffin. Tissue sections with a thickness of 2 lm were subjected to
Masson’s trichrome staining, and those with a thickness of 3 lm
were stained with hematoxylin-eosin (H&E) or subjected to immuno-
histochemical or immunohistofluorescence analysis. Immunohisto-
chemistry was carried out with antibodies to MelanA (mouse
monoclonal, ab731; Abcam, Cambridge, UK), to periostin (mouse
monoclonal, clone no. SS19C),16 or to a-SMA (rabbit polyclonal,
ab5694; Abcam), and immune complexes were detected with the
use of a Vectastain Elite ABC-HRP Kit and Mouse on Mouse
Immunodetection Kit (Vector, Burlingame, CA, USA). Immuno-
histofluorescence staining was carried out with antibodies to MelanA
(as above), to periostin (rabbit polyclonal, ab14041; Abcam), or to Ki-
67 (rabbit monoclonal, MA5-14520; Thermo Fisher Scientific, Wal-
tham, MA, USA) or with eFluor 660-conjugated antibodies to a-SMA
(mouse monoclonal, 50-9760-82; Thermo Fisher Scientific). Immune
complexes were detected with Alexa Fluor 488-, Alexa Fluor 555-,
or Alexa Fluor 594-conjugated goat antibodies to rabbit or mouse
IgG (Thermo Fisher Scientific), and nuclei were stained with DAPI
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(Sigma Chemical Co., St Louis, MO, USA). Tissue sections were
viewed with a Biorevo BZ-9000 fluorescence microscope (Keyence,
Osaka, Japan), a TissueFAXS Histo light microscope (TissueGnostics,
Vienna, Austria), or an FV1000-D confocal microscope (Olympus,
Tokyo, Japan). Tumor size (mm2) and cell counts were quantitated
with the use of BZ-X Analyzer and HistoQuest. Three random fields
for each of at least 3 mice per group were assessed for tumor size,
cell counts, and severity of fibrosis based on the Ashcroft score.17
2.6 | Statistical analysis
Data are presented as means  SD and were analyzed with Stu-
dent’s t test or one-way ANOVA followed by Dunnett’s multiple
comparison test as carried out with GraphPad Prism version 6. P-
value of <.05 was considered statistically significant.
2.7 | Additional methods
Isolation and culture of murine lung fibroblasts, in vivo studies for
analysis of the effect of giving ASO on metastasis by B16-BL6,
quantitative RT-PCR analysis, and periostin ASO treatment in vitro
are described in Appendix S1.
3 | RESULTS
3.1 | Expression of periostin and number of a-
SMA+ cells increase with progression of bleomycin-
induced lung fibrosis
To examine the relation between fibrotic change and periostin
expression in mouse lung, we studied a well-characterized mouse
model of lung fibrosis based on bleomycin treatment.18 C57BL/6J
mice that received a single intratracheal injection of bleomycin were
subjected to histological analysis of the lung every 4 days for up to
16 days (Figure 1A). An increase in interstitial thickness was appar-
ent from day 4 and was followed by an increase in fibrosis, with
marked accumulation of connective tissue and collapse of alveolar
structure being observed from day 12. Ashcroft score for severity of
fibrosis was significantly increased from day 8 to day 16 compared
with that at day 0 (Figure 1B). Progression of lung fibrosis was
accompanied by a pronounced increase in the number of periostin+
cells that was first apparent at day 8 (Figure 1A,C). Number of a-
SMA+ myofibroblasts, which are key mediators of fibrosis,19 was also
increased in fibrotic lesions at day 8 but had decreased again at day
12 (Figure 1D,E).
3.2 | Bleomycin-induced lung fibrosis promotes
metastatic colonization by melanoma cells in
association with increased periostin expression
Lung metastatic colonization was previously shown to be increased
in mice treated with bleomycin before injection of 4T1 murine breast
tumor cells with a high lung metastatic potential, suggesting that a
fibrotic microenvironment may serve as a niche conducive to tumor
cell colonization.5 To investigate whether bleomycin treatment pro-
motes lung colonization by tumor cells with a low metastatic poten-
tial, such as B16 murine melanoma cells, we injected B16 cells into
the tail vein of mice 10 days after giving intratracheal bleomycin
(Figure 2A). Number of macrometastases and tumor burden deter-
mined 11 days later were significantly increased in the bleomycin-
treated mice compared with saline-treated control animals, in which
metastasis was rarely observed (Figure 2B,C), indicating that a
fibrotic environment promotes metastatic colonization and propaga-
tion of tumor cells with a low metastatic ability. Immunohistofluores-
cence analysis showed expression of periostin at metastatic sites
(those positive for MelanA+ melanoma cells) in the lungs not only of
bleomycin-treated mice but also in those of saline-treated controls
(Figure 2D) in spite of the fact that expression of periostin was quite
low in B16 cells (Figure S1), implying that periostin in metastatic
colonization of the lung is produced by fibroblasts.
3.3 | Periostin ASO suppresses fibrosis and the
increase in a-SMA+ cell number in lungs of
bleomycin-treated mice
To clarify the role of periostin in lung fibrosis induced by bleomycin,
we gave an ASO targeting periostin mRNA to inhibit periostin
expression.20 We confirmed that periostin ASO suppressed Postn
mRNA expression in lung fibroblasts in vitro (Figure S2). Mice were
thus injected intratracheally with a control or periostin ASO on day
2 and day 7 after receiving bleomycin, and the lung was subjected
to histological analysis on day 8. We found that periostin ASO treat-
ment attenuated lung fibrosis as well as periostin expression induced
by bleomycin (Figure 3A). Both the Ashcroft score and the percent-
age of periostin+ cells were thus significantly lower in the mice trea-
ted with periostin ASO than in those that received control ASO
(Figure 3B,C). The number of a-SMA+ cells in fibrotic lesions was
also reduced by periostin ASO treatment (Figure 3D). Of note, cells
positive for both Ki-67 and a-SMA, corresponding to proliferating
myofibroblasts, were observed less frequently in fibrotic loci of peri-
ostin ASO-treated mice (Figure 3E). These data suggested that peri-
ostin plays a key role in the development of lung fibrosis and
myofibroblast activation in response to bleomycin.
3.4 | Periostin ASO suppresses lung metastasis of
B16 murine melanoma cells promoted by lung fibrosis
Given that periostin ASO attenuated lung fibrosis induced by bleo-
mycin, we examined whether knockdown of periostin expression
might also inhibit metastatic colonization of the lung promoted by
pulmonary fibrosis. Mice were treated intratracheally with control or
periostin ASO at 2 and 7 days after receiving bleomycin and were
injected i.v. with B16 cells at 10 days (Figure 4A). Number of
macrometastases (Figure 4B) as well as tumor burden (Figure 4C) in
the lung at day 21 was significantly reduced in the periostin ASO-
treated mice compared with the control animals. These results thus
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indicated that inhibition of periostin expression suppressed meta-
static colonization of the lung by tumor cells by preventing forma-
tion of a fibrotic milieu that can serve as a premetastatic niche.
4 | DISCUSSION
We have herein confirmed that periostin is widely expressed in
fibrotic lesions of C57BL/6J mice with bleomycin-induced lung fibro-
sis. Periostin expression has previously been shown to be up-regu-
lated in lung mesenchymal cells such as fibroblasts and fibrocytes in
mice treated with bleomycin,21 in monocytes, fibrocytes, and fibrob-
lasts of the lung in patients with idiopathic pulmonary fibrosis,15 and
in bronchial epithelial cells of such patients and individuals with
asthma.22 Bleomycin treatment has also been found to increase the
expression of various inflammatory mediators including transforming
growth factor-b1 (TGF-b1), interleukin (IL)-4, and IL-13.23 Up-regula-
tion of periostin production in lung cells might thus be mediated
through activation of TGF-b or JAK-STAT signaling pathways.21,24
Myofibroblasts play the leading role in tissue remodeling and pro-
duction of ECM during lung fibrogenesis. Consistent with this sce-
nario, we found that the number of a-SMA+ myofibroblasts
increased concomitantly with that of periostin+ cells in the lung of
bleomycin-treated mice. Myofibroblasts that originate from resident
stromal cells are activated by various stimuli including chemokines,
ECM proteins, and mechanical stress.25 Periostin up-regulates
a-SMA expression in murine skin fibroblasts through activation of
integrin-FAK signaling.26 Periostin also promotes the induction of
myofibroblast differentiation by cytokines such as TGF-b1 and con-
nective tissue growth factor, the latter of which is secreted from
lung mesenchymal cells in response to bleomycin stimulation.21 Peri-
ostin may therefore play an important role in bleomycin-induced
lung fibrosis through activation of myofibroblasts and consequent
ECM accumulation.
Metastatic colonization is thought to be problematic for tumor
cells because most of the cells die of maladaptation to the new
microenvironment which rejects tumor cells by multiple factors
including reactive oxygen species (ROS), hypoxia, inhibitory
F IGURE 1 Up-regulation of periostin expression associated with progression of lung fibrosis. A, Serial sections of the lung from non-treated
mice (Day 0) and mice killed 4, 8, 12, or 16 d after receiving intratracheal bleomycin were subjected to hematoxylin-eosin (H&E) and Masson’s
trichrome staining as well as to immunohistochemical analysis with antibodies to periostin. Scale bars, 100 lm. B, Ashcroft score for lung
fibrosis and C, percentage of periostin-positive cells in the lungs of mice treated as in (A). D, Sections of the lung from mice treated as in A,
were subjected to immunohistochemical analysis of a-smooth muscle actin (a-SMA) expression. Scale bars, 50 lm. E, Density of a-SMA-
positive cells in fibrotic areas of the lung from mice treated as in (A). All quantitative data are means  SD for 4 mice in each group.
**P < .01, ***P < .001 (one-way ANOVA)
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cytokines and immune cells,27 and only a few of those that survive
go on to give rise to macrometastases.28 ROS is known to be a
major contributor to prevention of tumor cell metastasis. It is known
that some kinds of ECM proteins such as laminin and fibronectin
stimulate the generation of ROS by integrin-mediated signaling path-
way.29 In contrast, fibulin-5 reduced ROS production in pancreatic
cancer cells by competing with fibronectin for binding to integrin.30
Therefore, an ECM protein periostin might also be involved in the
regulation of ROS level in the premetastatic niche. An experimental
mouse model showed that only 0.02% of melanoma cells injected
into the portal vein were able to form multicellular foci in the
liver.31 Similarly, we found that macrometastases in saline-treated
mouse lung were rarely observed after tail vein injection of B16
melanoma cells. In contrast, a large number of macrometastases was
evident in the bleomycin-treated lung, suggesting that the genera-
tion of a fibrotic milieu in the lung by giving bleomycin promoted
metastatic colonization by melanoma cells. To assess the role of
periostin in the development of lung fibrosis and consequent promo-
tion of tumor cell colonization, we gave an ASO targeting periostin
mRNA intratracheally in order to inhibit periostin expression in the
lung. ASO were first developed in the form of a short DNA frag-
ment tested in vitro in 1978,32 and they have recently proven thera-
peutically effective in several clinical trials for conditions such as
hypercholesterolemia33 and malignant tumors.34,35 Current gapmer
ASO, including those used in the present study, contain both a cen-
tral deoxynucleotide phosphorothioate gap that allows them to pro-
mote cleavage of target mRNA by recruiting ribonuclease H to the
ASO/target mRNA heteroduplex site as well as 50- and 30- wing
regions modified with 20-O-methoxyethyl or 20-O-methyl residues
that increase both resistance to degradation and affinity for the tar-
get mRNA.36 Although the delivery of ASO to the desired organs
and cells remains to be optimized, these molecules have the poten-
tial to be developed into unprecedented therapies given their high
target specificity.37
F IGURE 2 Bleomycin-induced lung fibrosis promotes lung metastasis of B16 melanoma cells. A, Schematic representation of the
experimental protocol. Mice received bleomycin (BLM) or saline intratracheally (i.t.) 10 d before injection of B16 murine melanoma cells into
the tail vein. Mice were killed for analysis 11 d after cell injection. B, Representative images of the lungs of mice at day 21 and quantification
of the number of macroscopically detectable lung metastases. Scale bars, 5 mm. Quantitative data are for individual mice and means  SD for
each group. C, Hematoxylin-eosin (H&E) staining and immunohistochemical analysis of MelanA as well as quantification of the percentage
tumor area based on MelanA staining for the lungs of mice killed on day 21. The boxed area in the low-magnification image of bleomycin-
treated lung tissue is shown at higher magnification in the images on the right. Scale bars represent 1 mm and 100 lm for low- and high-
magnification images, respectively. Quantitative data are means  SD for 5 (bleomycin) or 6 (saline) mice. D, Representative
immunohistofluorescence staining of MelanA and periostin in metastatic tumors from saline- or bleomycin-treated mice on day 21. Nuclei
were stained with DAPI. Scale bars, 100 lm. *P < .05, **P < .01 (Student’s t test)
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In the present study, we directed periostin ASO to lung cells
by intratracheal administration. Such periostin ASO administration
attenuated fibrosis and reduced the number of active myofibrob-
lasts in the lung of bleomycin-stimulated mice. Furthermore, we
found that the periostin ASO significantly inhibited metastatic col-
onization of the bleomycin-treated lung by melanoma cells. In
addition, we carried out similar experiments using mice without
BLM pretreatment and B16-BL6 cells which have a high meta-
static potential (Figure S3A). Although the impact was somewhat
limited, we observed that the number of lung macrometastases by
B16-BL6 cells was decreased by periostin ASO treatment (Fig-
ure S3B). Collectively, our data thus indicate that inhibition of
periostin expression ameliorated bleomycin-induced lung fibrosis
through suppression of myofibroblast differentiation, resulting in
attenuation of ECM production. These results therefore suggest
that periostin is one of the most important molecular contributors
for formation of a fibrotic milieu that supports lung colonization
by melanoma cells. In addition, we do not exclude other roles of
periostin, such as adhesion to melanoma cells and maintenance of
metastatic melanoma cells. At least, as an adhesion molecule, peri-
ostin is likely to associate with integrin of melanoma cells because
periostin was actually expressed around metastatic melanoma
regions in the lung (Figure 2D). Therefore, our data further
suggest the possibility that periostin has a function that directly
promotes metastatic colonization by melanoma cells even in
non-fibrotic lungs.
In summary, our results provide evidence that periostin is an
essential molecule for generation of bleomycin-induced lung fibrosis.
F IGURE 3 Effects of giving periostin antisense oligonucleotides (ASO) on the bleomycin-treated lung. A, Mice were injected intratracheally
with a control or periostin ASO at 2 and 7 d after receiving bleomycin and were killed for analysis on day 8. Serial sections of the lung were
stained with hematoxylin-eosin (H&E) and subjected to immunohistochemical analysis of periostin expression. Scale bars, 100 lm. B, Ashcroft
score for lung fibrosis in the mice on day 8. C, Quantification of the percentage of periostin-positive cells in the lung on day 8. D, Lung
sections from the mice on day 8 were subjected to immunohistochemical analysis for quantification of the density of a-smooth muscle actin
(a-SMA)-positive cells in fibrotic areas. Scale bars, 100 lm. E, Representative immunohistofluorescence staining of lung fibrotic lesions for a-
SMA and Ki-67 at day 8. Nuclei were stained with DAPI. Scale bars, 100 and 10 lm for low-magnification and high-magnification (insets)
images, respectively. All quantitative data are means  SD for 8 and 6 mice injected with the control or periostin ASO, respectively. *P < .05
(Student’s t test)
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Our results suggest that periostin promotes metastatic colonization
of the lung by melanoma cells. Furthermore, ASO-based therapies
that target periostin have the potential to suppress metastatic colo-
nization by preventing the formation of a fibrotic milieu able to
serve as a premetastatic niche.
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